Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2032

Chimeric Antigen Receptor (CAR) T-Cell Therapy market is currently driven by factors such as the rising incidence of cancer, a strong drug pipeline, rising number of healthcare settings that administer CAR T, improving safety and efficacy of current and emerging therapies, etc. CAR T-cell therapies have a potential to transform cancer treatment by using the immune system to fight diseases. CAR T therapy requires genetically engineering T cells (either a patient’s own or a donor’s) to express a chimeric antigen receptor that targets a particular tumor antigen.

The biggest factor catalyzing the growth of the market is the strong efficacy of these treatment. For instance, pediatric and young adult patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL) achieved an overall remission rate of 90 percent during the first 12 months with treatment with an anti-CD19 autologous CAR T therapy. However, in spite of, the convincing efficacy data in clinical trials, there are a number of  challenges impacting the commercialization of CAR Ts. These challenges include complex and costly manufacturing and supply chain, lengthy and logistically challenging patient journey, and reimbursement challenges. The (CAR) T-Cell Therapy market is set to be a transformative therapy in cancer care, but unleashing its potential will require placing strategic bets. Technological advances and manufacturing innovations are rapidly improving - with the prospects for CAR T to not only treat niche liquid tumors but a broader range of solid and liquid tumors in the near future. Market players that are able to make intelligent investments can significantly expand the number of patients they treat as well as the success rates of their therapies.

IMARC Group’s  new report "Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy across the seven major markets. According to the report the United States has the largest patient pool for Chimeric Antigen Receptor (CAR) T-Cell Therapy and also represents the largest market for Chimeric Antigen Receptor (CAR) T-Cell Therapy treatments. Furthermore, the current Chimeric Antigen Receptor (CAR) T-Cell Therapy treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Chimeric Antigen Receptor (CAR) T-Cell Therapy market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Sales of Various Drugs Across the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
  • Reimbursement Scenario in the Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
     

Chimeric Antigen Receptor (CAR) T-Cell Therapy:  In-Market and Pipeline Drugs

This  report also provides a detailed analysis of the current Chimeric Antigen Receptor (CAR) T-Cell Therapy marketed drugs and late-stage pipeline drugs.

  • In-Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Chimeric Antigen Receptor (CAR) T-Cell Therapy Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status
       

Key Questions Answered in this Report

 

Market Insights

  • How has the Chimeric Antigen Receptor (CAR) T-Cell Therapy market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market across the seven major markets in 2021 and how will it look like in 2032?
  • What is the growth rate of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market?

 

Epidemiology Insights

  • What is the size of the Chimeric Antigen Receptor (CAR) T-Cell Therapy patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Chimeric Antigen Receptor (CAR) T-Cell Therapy across the seven major markets?
  • What are the key factors driving the epidemiological trend of Chimeric Antigen Receptor (CAR) T-Cell Therapy?
  • What will be the growth rate of Chimeric Antigen Receptor (CAR) T-Cell Therapy patients across the seven major markets?

 

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their market performance?
  • What are the key pipeline Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their efficacies?
  • How safe are the late-stage pipeline Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs and what are their efficacies?
  • What are the current treatment guidelines for Chimeric Antigen Receptor (CAR) T-Cell Therapy drugs across the seven major markets?
  • Who are the key companies in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Chimeric Antigen Receptor (CAR) T-Cell Therapy market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Chimeric Antigen Receptor (CAR) T-Cell - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Patient Journey

7 Chimeric Antigen Receptor (CAR) T-Cell - Epidemiology and Patient Population
6.1 Epidemiology - Key Insights
6.2 Epidemiology Scenario - Top 7 Markets
6.2.1 Epidemiology Scenario (2017-2021)
6.2.2 Epidemiology Forecast (2022-2032)
6.3 Epidemiology Scenario - United States
6.3.1 Epidemiology Scenario (2017-2021)
6.3.2 Epidemiology Forecast (2022-2032)
6.4 Epidemiology Scenario - Germany
6.4.1 Epidemiology Scenario (2017-2021)
6.4.2 Epidemiology Forecast (2022-2032)
6.5 Epidemiology Scenario - France
6.5.1 Epidemiology Scenario (2017-2021)
6.5.2 Epidemiology Forecast (2022-2032)
6.6 Epidemiology Scenario - United Kingdom
6.6.1 Epidemiology Scenario (2017-2021)
6.6.2 Epidemiology Forecast (2022-2032)
6.7 Epidemiology Scenario - Italy
6.6.1 Epidemiology Scenario (2017-2021)
6.6.2 Epidemiology Forecast (2022-2032)
6.8 Epidemiology Scenario - Spain
6.8.1 Epidemiology Scenario (2017-2021)
6.8.2 Epidemiology Forecast (2022-2032)
6.9 Epidemiology Scenario - Japan
6.9.1 Epidemiology Scenario (2017-2021)
6.9.2 Epidemiology Forecast (2022-2032)

7 Chimeric Antigen Receptor (CAR) T-Cell - Treatment Algorithm, Guidelines, and Medical Practices
7.1 Chimeric Antigen Receptor (CAR) T-Cell Guidelines, Management and Treatment
7.2 Chimeric Antigen Receptor (CAR) T-Cell Treatment Algorithm

8 Chimeric Antigen Receptor (CAR) T-Cell - Unmet Needs

9 Chimeric Antigen Receptor (CAR) T-Cell - Key Endpoints of Treatment

10 Chimeric Antigen Receptor (CAR) T-Cell - Marketed Products
10.1 List of Chimeric Antigen Receptor (CAR) T-Cell Marketed Drugs Across the Top 7 Markets
10.1.1    Drug Name - Company Name
10.1.1.1 Drug Overview
10.1.1.2 Mechanism of Action
10.1.1.3 Regulatory Status
10.1.1.4 Clinical Trial Results
10.1.1.5 Sales Across Major Markets
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

11 Chimeric Antigen Receptor (CAR) T-Cell - Pipeline Drugs
11.1 List of Chimeric Antigen Receptor (CAR) T-Cell Pipeline Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12. Chimeric Antigen Receptor (CAR) T-Cell - Attribute Analysis of Key Marketed and Pipeline Drugs

13 Chimeric Antigen Receptor (CAR) T-Cell - Market Scenario
13.1 Market Scenario - Key Insights
13.2 Market Scenario - Top 7 Markets
13.2.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.2.1.1 Market Size (2017-2021)
13.2.1.2 Market Forecast (2022-2032)
13.2.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.2.2.1 Market Size by Therapies (2017-2021)
13.2.2.2 Market Forecast by Therapies (2022-2032
13.3 Market Scenario - United States
13.3.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.3.1.1 Market Size (2017-2021)
13.3.1.2 Market Forecast (2022-2032)
13.3.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.3.2.1 Market Size by Therapies (2017-2021)
13.3.2.2 Market Forecast by Therapies (2022-2032)
13.3.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.4 Market Scenario - Germany
13.4.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.4.1.1 Market Size (2017-2021)
13.4.1.2 Market Forecast (2022-2032)
13.4.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.4.2.1 Market Size by Therapies (2017-2021)
13.4.2.2 Market Forecast by Therapies (2022-2032)
13.4.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.5 Market Scenario - France
13.5.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.5.1.1 Market Size (2017-2021)
13.5.1.2 Market Forecast (2022-2032)
13.5.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.5.2.1 Market Size by Therapies (2017-2021)
13.5.2.2 Market Forecast by Therapies (2022-2032)
13.5.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.6 Market Scenario - United Kingdom
13.6.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.6.1.1 Market Size (2017-2021)
13.6.1.2 Market Forecast (2022-2032)
13.6.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.6.2.1 Market Size by Therapies (2017-2021)
13.6.2.2 Market Forecast by Therapies (2022-2032)
13.6.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.7 Market Scenario - Italy
13.7.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.7.1.1 Market Size (2017-2021)
13.7.1.2 Market Forecast (2022-2032)
13.7.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.7.2.1 Market Size by Therapies (2017-2021)
13.7.2.2 Market Forecast by Therapies (2022-2032)
13.7.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.8 Market Scenario - Spain
13.8.1    Chimeric Antigen Receptor (CAR) T-Cell - Market Size
13.8.1.1 Market Size (2017-2021)
13.8.1.2 Market Forecast (2022-2032)
13.8.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.8.2.1 Market Size by Therapies (2017-2021)
13.8.2.2 Market Forecast by Therapies (2022-2032)
13.8.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview
13.9   Market Scenario - Japan
13.9.1    Chimeric Antigen Receptor (CAR) T-Cell  - Market Size
13.9.1.1 Market Size (2017-2021)
13.9.1.2 Market Forecast (2022-2032)
13.9.2    Chimeric Antigen Receptor (CAR) T-Cell - Market Size by Therapies
13.9.2.1 Market Size by Therapies (2017-2021)
13.9.2.2 Market Forecast by Therapies (2022-2032)
13.9.3    Chimeric Antigen Receptor (CAR) T-Cell - Access and Reimbursement Overview

14 Chimeric Antigen Receptor (CAR) T-Cell - Recent Events and Inputs From Key Opinion Leaders

15 Chimeric Antigen Receptor (CAR) T-Cell Market - SWOT Analysis
15.1 Strengths
15.2 Weaknesses
15.3 Opportunities
15.4 Threats     

16 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4